MX2023007587A - Tratamiento de enfermedades hepaticas con inhibidores de efectores b tipo dffa que inducen la muerte celular (cideb). - Google Patents

Tratamiento de enfermedades hepaticas con inhibidores de efectores b tipo dffa que inducen la muerte celular (cideb).

Info

Publication number
MX2023007587A
MX2023007587A MX2023007587A MX2023007587A MX2023007587A MX 2023007587 A MX2023007587 A MX 2023007587A MX 2023007587 A MX2023007587 A MX 2023007587A MX 2023007587 A MX2023007587 A MX 2023007587A MX 2023007587 A MX2023007587 A MX 2023007587A
Authority
MX
Mexico
Prior art keywords
cideb
dffa
treatment
type
cell death
Prior art date
Application number
MX2023007587A
Other languages
English (en)
Spanish (es)
Inventor
Aris Baras
Luca Andrea Lotta
Olukayode Sosina
Niek Verweij
Mary Haas
Jonas Nielsen
Adam Locke
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MX2023007587A publication Critical patent/MX2023007587A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/465—Hydrolases (3) acting on ester bonds (3.1), e.g. lipases, ribonucleases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844—Nucleic acid amplification reactions
    • C12Q1/6858—Allele-specific amplification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6869—Methods for sequencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
    • C12N2310/122—Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/31—Combination therapy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/34—Allele or polymorphism specific uses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Lubricants (AREA)
  • Pens And Brushes (AREA)
MX2023007587A 2020-12-23 2021-12-22 Tratamiento de enfermedades hepaticas con inhibidores de efectores b tipo dffa que inducen la muerte celular (cideb). MX2023007587A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202063129725P 2020-12-23 2020-12-23
US202163149258P 2021-02-13 2021-02-13
US202163246101P 2021-09-20 2021-09-20
US202163257137P 2021-10-19 2021-10-19
PCT/US2021/064987 WO2022140624A1 (en) 2020-12-23 2021-12-22 Treatment of liver diseases with cell death inducing dffa like effector b (cideb) inhibitors

Publications (1)

Publication Number Publication Date
MX2023007587A true MX2023007587A (es) 2023-09-21

Family

ID=80001294

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023007587A MX2023007587A (es) 2020-12-23 2021-12-22 Tratamiento de enfermedades hepaticas con inhibidores de efectores b tipo dffa que inducen la muerte celular (cideb).

Country Status (8)

Country Link
US (3) US12018259B2 (https=)
EP (1) EP4267739A1 (https=)
JP (1) JP2024502282A (https=)
KR (1) KR20230124915A (https=)
CA (1) CA3201624A1 (https=)
IL (1) IL303536A (https=)
MX (1) MX2023007587A (https=)
WO (1) WO2022140624A1 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024538859A (ja) * 2021-08-31 2024-10-24 アルナイラム ファーマシューティカルズ， インコーポレイテッド 細胞死誘導ＤＦＦＡ様エフェクターＢ（ＣＩＤＥＢ）ｉＲＮＡ組成物およびその使用方法
US20230193392A1 (en) 2021-12-20 2023-06-22 Regeneron Pharmaceuticals, Inc. Methods Of Identifying And Evaluating Liver Inflammation And Liver Fibrosis In A Subject By Determining A Stratified Score Based On Gene Expression
CN119278205A (zh) * 2022-04-07 2025-01-07 得克萨斯大学体系董事会 用靶向CIDEB的siRNA治疗肝病的组合物和方法
US20240071625A1 (en) * 2022-08-29 2024-02-29 Cedars-Sinai Medical Center Nafld identification and prediction systems and methods
WO2024109722A1 (zh) * 2022-11-21 2024-05-30 广州必贝特医药股份有限公司 用于抑制CIDEB基因表达的siRNA、药物及其应用
WO2024188164A1 (en) * 2023-03-10 2024-09-19 Shanghai Argo Biopharmaceutical Co., Ltd. Compositions and methods for inhibiting expression of cell death inducing dffa like effector b (cideb)
AU2024243110A1 (en) * 2023-04-07 2025-11-06 Rona Bioscience, Limited Dsrna molecule for regulating expression of cideb mrna
CN118063533B (zh) * 2023-09-18 2024-08-27 广州必贝特医药股份有限公司 修饰的核苷酸化合物、其寡聚核苷酸及其应用
WO2025162435A1 (en) * 2024-02-02 2025-08-07 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treatment of liver disease
WO2025178854A2 (en) * 2024-02-19 2025-08-28 Flagship Pioneering Innovations Vii, Llc Rnai agents targeting cideb and related methods
WO2025245188A2 (en) * 2024-05-21 2025-11-27 Flagship Pioneering Innovations Vii, Llc Methods of treating liver steatosis and non-alcoholic fatty liver disease

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007538093A (ja) 2004-05-19 2007-12-27 ナチュラル ソース インターナショナル 前立腺癌の治療および予防におけるフラボペレイリンとアルストニンとの併用
EP2105511A1 (en) 2008-03-28 2009-09-30 Fraunhofer-Gesellschaft zur Förderung der Angewandten Forschung e.V. Medicament compositions and substances for treatment and identifying adenocarcinoma of the lung
CN102300578A (zh) 2008-12-01 2011-12-28 延寿有限责任公司 用于改变健康、安康和寿命的方法和组合物
KR20110111474A (ko) 2009-01-09 2011-10-11 더 리젠츠 오브 더 유니버시티 오브 미시간 암에서의 반복적 유전자 융합체
FR2940910A1 (fr) 2009-01-09 2010-07-16 Vetoquinol Sa Nouveau comprime a base de s-adenosyl-methionine
US8445207B2 (en) 2009-04-07 2013-05-21 Korea Institute Of Science And Technology Genes based on thalidomide, valproic acid and methotrexate treatment for screening of drug inducing teratogenicity and screening method using thereof
CN102481271A (zh) 2009-05-11 2012-05-30 博格生物系统有限责任公司 利用表观代谢转变剂、多维细胞内分子或环境影响剂治疗代谢障碍的方法
KR101886342B1 (ko) 2010-11-30 2018-08-10 (주)아모레퍼시픽 피부 노화와 관련된 유전자 및 피부 노화를 방지하는 물질을 스크리닝하는 방법
WO2012149386A1 (en) 2011-04-27 2012-11-01 Isis Pharmaceuticals, Inc. Modulation of cideb expression
WO2013022821A1 (en) 2011-08-05 2013-02-14 Gen-Probe Incorporated Antiandrogen therapy monitoring methods and compositions
WO2013022872A1 (en) 2011-08-10 2013-02-14 Celgene Corporation Gene methylation biomarkers and methods of use thereof
US20140342946A1 (en) 2011-12-31 2014-11-20 Moni Abraham Kuriakose Diagnostic tests for predicting prognosis, recurrence, resistance or sensitivity to therapy and metastatic status in cancer
WO2014089121A2 (en) 2012-12-03 2014-06-12 Thomas Ichim Retrograde delivery of cells and nucleic acids for treatment of cardiovascular diseases
CA2976445A1 (en) * 2015-02-13 2016-08-18 Alnylam Pharmaceuticals, Inc. Patatin-like phospholipase domain containing 3 (pnpla3) irna compositions and methods of use thereof
WO2016175913A1 (en) 2015-04-27 2016-11-03 Roseman University Of Health Sciences Methods for therapeutic targeting of circulating tumor cells during hemodialysis
WO2017067477A1 (en) 2015-10-20 2017-04-27 Hung-Cheng Lai Methods for making diagnosis and/or prognosis of gynecologic neoplasm
US20190071795A1 (en) 2016-03-09 2019-03-07 Molecular Stethoscope, Inc. Methods and systems for detecting tissue conditions
WO2017191274A2 (en) 2016-05-04 2017-11-09 Curevac Ag Rna encoding a therapeutic protein
AU2018348195B2 (en) 2017-10-11 2025-05-15 Regeneron Pharmaceuticals, Inc. Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variation
WO2019140380A1 (en) 2018-01-12 2019-07-18 Kymera Therapeutics, Inc. Protein degraders and uses thereof
US20210000906A1 (en) 2018-03-21 2021-01-07 Ionis Pharmaceuticals, Inc. Modulation of hsd17b13 expression
AU2019239971B2 (en) 2018-03-21 2025-09-11 Regeneron Pharmaceuticals, Inc. 17beta-hydroxysteroid dehydrogenase type 13 (HSD17b13) iRNA compositions and methods of use thereof
MX2020013994A (es) 2018-06-22 2021-05-27 Bluestar Genomics Inc Análisis de hidroximetilación de muestras de ácido nucleico sin células para asignación de tejido de origen, y métodos relacionados de uso.
US11021545B2 (en) 2018-07-31 2021-06-01 The Regents Of The University Of California Multimodal cancer therapy comprising chimeric viral/nonviral nanoparticles and anticancer agents
KR102769565B1 (ko) 2018-09-19 2025-02-20 애로우헤드 파마슈티컬스 인코포레이티드 17베타-HSD 유형 13- (HSD17B13)의 발현을 억제하기 위한 RNAi 작용제, 그의 조성물, 및 사용 방법

Also Published As

Publication number Publication date
WO2022140624A1 (en) 2022-06-30
AU2021410768A1 (en) 2023-06-22
US11773393B2 (en) 2023-10-03
US12018259B2 (en) 2024-06-25
US20220220474A1 (en) 2022-07-14
IL303536A (en) 2023-08-01
AU2021410768A9 (en) 2025-01-09
US20220282253A1 (en) 2022-09-08
KR20230124915A (ko) 2023-08-28
EP4267739A1 (en) 2023-11-01
US20240376471A1 (en) 2024-11-14
JP2024502282A (ja) 2024-01-18
CA3201624A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
MX2023007587A (es) Tratamiento de enfermedades hepaticas con inhibidores de efectores b tipo dffa que inducen la muerte celular (cideb).
MX2023014405A (es) Terapia combinada que comprende un inhibidor de mat2a y un inhibidor de prmt de tipo ii.
MX2024004195A (es) Biomarcadores de metabolitos para enfermedades asociadas con el sistema de activacion por contacto.
BR112014018331A8 (pt) Biomarcadores e terapias combinadas usando vírus oncolítico e imunomodulação
CL2020002161A1 (es) Composiciones y métodos para tratar el deterioro auditivo no asociado con la edad en un sujeto humano.
MX2019010958A (es) Metodos de tratamiento de tumores.
MX2020007060A (es) Compuestos, composiciones y metodos para tratar enfermedades que involucren tejidos con enfermedades acidas o hipoxicas.
MX2020000604A (es) Métodos terapéuticos y de diagnóstico para el cáncer.
MX2020009140A (es) Metodos para el tratamiento de enfermedades oculares.
CL2017003069A1 (es) Métodos para diagnosticar y tratar el cáncer.
MX2020002553A (es) Metodos de diagnostico y terapeuticos para el cancer.
BR112021021921A2 (pt) Agente, uso de um agente e método de tratamento ou prevenção de uma doença metabólica
PE20191359A1 (es) Uso de biomarcadores en la identificacion de pacientes con cancer que seran sensibles al tratamiento con un inhibidor de prmt5
BR112019025056A2 (pt) Inibidores de fgfr2 para o tratamento de colangiocarcinoma
CY1119317T1 (el) Συνθεση για τοπικη εφαρμογη, χρησεις αυτης, συσκευη εφαρμογης και kit μερων
NI202000085A (es) Moduladores de la expresión de apol1
MX2024013120A (es) Analisis del transcriptoma para el tratamiento de la inflamacion
MX2020007852A (es) Metodos para el tratamiento de la atrofia muscular espinal.
CL2022000262A1 (es) Métodos de identificación de pacientes con posibilidad de beneficiarse de un tratamiento con un inhibidor de la telomerasa (divisional de la solicitud no. 202100251)
MX2022013233A (es) Metodo de seleccion de pacientes para tratamiento con una combinacion de un inhibidor de axl y un modulador de punto de control inmunitario.
BR112018009664A2 (pt) plataforma de rastreamento de resultados de pacientes
CO2021005234A2 (es) Métodos de tratamiento
CO2021005207A2 (es) Métodos de tratamiento
EA202192176A1 (ru) Нарушения, опосредованные интерфероном i типа
AR117094A1 (es) Moduladores de expresión irf5